Ironwood rises after US sets Medicare price for constipation drug
ReutersNov 26, 2025 12:18 PM
Shares of drugmaker Ironwood Pharmaceuticals' IRWD.O shares rise 1.3% to $3.17 premarket
Co says U.S. Department of Health and Human Services has set the new Medicare price for co's Linzess at $136 for a 30-day supply
Co's Linzess treats chronic constipation and irritable bowel syndrome with constipation - IRWD
New price will apply from Jan. 1, 2027 under Inflation Reduction Act, co says
Co says revised price aligns with its expectations
Up to last close, stock down ~30% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Cathie Wood Predicts Bitcoin Has Bottomed. Is Now The Best Time to Buy? How to Buy BTC?
Purchasing Bitcoin is generally divided into three stages: pre-transaction, during transaction, and post-transaction. Each stage requires careful attention, as losses can easily arise from operational errors, pitfalls, and other factors.TradingKey
Fri, Dec 19
Japan Central Bank Rate Hike To Three-Decade High Imminent, How Will The Market Go? Which Assets Most Affected?
As global monetary policy divergence enters a critical phase, the Bank of Japan (BoJ) is anticipated to raise its benchmark interest rate at the monetary policy meeting on December 19, 2025, by 25 basis points to 0.75% , marking its highest level in nearly 30 years.TradingKey
Thu, Dec 18
SpaceX and Tesla’s Strategic Convergence: Why Musk Must Push for a SpaceX IPO Now
Discover why the SpaceX IPO is a strategic booster for Tesla rather than a financial threat. This analysis explores how Elon Musk’s $1.5 trillion valuation goal funds the Mars Plan while empowering Tesla’s AI, FSD, and Optimus robots through Starlink and orbital computing.TradingKey
Wed, Dec 17
Tradingkey
